BlackRock Inc. Has $29.85 Million Position in MiniMed Group Inc $MMED

Key Points

• BlackRock increased its MiniMed Group stake by 7,527.5% in the second quarter, acquiring 1.97 million additional shares for a total position worth approximately $29.85 million, or 0.71% of the company.
• MiniMed reported strong fiscal 2027 momentum, with quarterly sales rising about 17% year over year and management raising its organic revenue-growth outlook. The company also cited several product-development catalysts, including FDA, CE Mark, clinical-trial and IDE milestones.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and 13 Buy ratings, although target prices vary widely. BTIG raised its target to $28, while the consensus target is near $21.85—below the referenced $22.42 share price.

BlackRock Inc. grew its stake in MiniMed Group Inc (NASDAQ:MMED - Free Report) by 7,527.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,996,489 shares of the company's stock after purchasing an additional 1,970,314 shares during the period. BlackRock Inc. owned approximately 0.71% of MiniMed Group worth $29,848,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, Bank of New York Mellon Corp acquired a new position in MiniMed Group during the second quarter worth $1,058,000.

MiniMed Group Price Performance

Shares of MMED opened at $22.42 on Wednesday. The company has a market cap of $6.31 billion and a price-to-earnings ratio of -32.97. MiniMed Group Inc has a 52 week low of $10.65 and a 52 week high of $22.74. The company has a fifty day moving average price of $17.65.

MiniMed Group (NASDAQ:MMED - Get Free Report) last posted its quarterly earnings results on Wednesday, June 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.46). The company had revenue of $837.00 million during the quarter. The firm's quarterly revenue was up 15.6% on a year-over-year basis. On average, equities analysts forecast that MiniMed Group Inc will post 0.66 earnings per share for the current fiscal year.

Key Headlines Impacting MiniMed Group

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: MiniMed reported fiscal Q1 2027 net sales of approximately $843 million, up 17% year over year, while U.S. organic sales growth accelerated to 13%. International sales also remained strong, rising 18% as reported and 17% organically. MiniMed Delivers Strong Start to Fiscal Year 2027 with U.S. Growth Acceleration
• Positive Sentiment: Quarterly adjusted EPS exceeded analyst expectations, reinforcing the growth narrative after the company’s prior earnings shortfall. Management also raised its fiscal 2027 organic revenue-growth guidance. MiniMed Group Q1 2027 EPS Tops Expectations, Revenue Up 17%
• Positive Sentiment: The company reported multiple pipeline catalysts: an FDA submission for MiniMed Fit™, CE Mark progress for MiniMed Flex™, completion of pivotal-trial enrollment for the Vivera™ FCL system, and IDE approval for a next-generation extended-wear sensor. These developments could support future product launches and revenue growth. MiniMed Group Releases Q1 2027 Financial Results
• Positive Sentiment: BTIG Research raised its price target from $25 to $28 and maintained a “buy” rating, implying meaningful upside from the referenced $22.42 share price. BTIG Raises MiniMed Group Price Target
• Neutral Sentiment: The analyst consensus target is $21.62, below the referenced share price, indicating that broader brokerage expectations remain more cautious than BTIG’s updated target. MiniMed Group Receives Consensus Target Price

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Piper Sandler reiterated a "neutral" rating and set a $16.00 target price on shares of MiniMed Group in a research report on Thursday, June 4th. UBS Group initiated coverage on shares of MiniMed Group in a research note on Tuesday, July 28th. They issued a "buy" rating and a $25.00 target price for the company. BTIG Research boosted their target price on MiniMed Group from $25.00 to $28.00 and gave the stock a "buy" rating in a report on Tuesday. Wells Fargo & Company decreased their price target on MiniMed Group from $26.00 to $22.00 and set an "overweight" rating on the stock in a research report on Thursday, June 4th. Finally, Bank of America cut their price objective on MiniMed Group from $27.00 to $20.00 and set a "buy" rating for the company in a research report on Monday, May 18th. Thirteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $21.85.

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.

Want to see what other hedge funds are holding MMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MiniMed Group Inc (NASDAQ:MMED - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source